Generic drug companies cannot launch their enzalutamide products in the Netherlands. In the pan-European dispute over prostate cancer drug Xtandi, the District Court The Hague upheld a basic patent
industry. How did we get the patent granted? Rather than dismissing her chances of getting patent protection, I faced the challenge with techniques I’ve developed to patent other subject matter that is